Improving the in vivo predictability of an on-line HPLC stable free radical decoloration assay for antioxidant activity in methanol-buffer medium

The pivotal role of ROS (reactive oxygen species) in various (patho)physiological processes has stimulated research on the potential of intervening in these processes with antioxidants (AO). In vitro model systems to investigate AO activity against the various ROS are a valuable tool in classifying antioxidants. To improve the in vivo predictability of the results obtained, we have modified and characterized the widely used DPPH (2,2'-diphenyl-1-picrylhydrazyl) on-line decoloration assay. Previous investigations using the DPPH reaction in a pure methanolic medium exhibit slow kinetics and a reaction going to completion. In this study, a medium which includes an aqueous buffer at physiological pH has been applied, resulting in the rapid establishment of equilibrium. The results obtained in an aqueous medium at physiological pH are expected to be more relevant for extrapolation to in vivo circumstances than previously published findings. The antioxidants investigated are classified according to the results obtained and the relevance of their behavior to in vivo situations is discussed. Special emphasis is put on the significance of the results for prediction of redox-cycling characteristics and structure-activity relationships.     

Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase,type II,beta

Phosphatidylinositol-5-phosphate 4-kinase, type II, beta (PIP5K2B) is linked to the pathogenesis of obesity, insulin resistance and diabetes. Here, we describe the identification of a novel pyrimidine-2,4-diamine PIP5K2B inhibitor, designated SAR088. The compound was identified by high-throughput screening and subsequently characterized in vitro and in vivo. SAR088 showed reasonable potency, selectivity and physicochemical properties in enzymatic and cellular assays. In vivo, SAR088 lowered blood glucose levels of obese and hyperglycemic male Zucker diabetic fatty rats treated for 3 weeks. Thus, SAR088 represents the first orally available and in vivo active PIP5K2B inhibitor and provides an excellent starting point for the development of potent and selective PIP5K2B inhibitors for the treatment of insulin resistance and diabetes.     

Infection of transformable cells ofHaemophilus influenzae by bacteriophage and bacteriophage DNA

Summary A phage HP1, infecting transformable cells ofHaemophilus influenzae Rd, has been isolated. The general properties of the wild type and of a clear plaquemutantc1 employed for most of the experiments are described. Phage DNA is infective for transformableHaemophilus cells with an efficiency (plaqueforming units of the original phage recovered as DNA-infected cells) of up to 6×10^–3. The competence ofHaemophilus cells for infection with phage DNA parallels the competence for transformation with bacterial DNA.Both HP1 and thec1 mutant are able to lysogenize their host, and the lysogenic cells are readily induced by UV. Competent non-lysogenicHaemophilus cells can be infected by DNA of lysogenic cells, thereby giving rise to phage progeny. Thus, the phage genetic material can be introduced into competentHaemophilus cells in three different ways: injection from intact phage, and infection with either phage DNA or with bacterial DNA carrying the prophage.The UV inactivation curves for infectious phage DNA and for complete phages are similar, both indicating the occurrance of host-cell reactivation. Photoreactivationin vitro of infectious phage DNA takes place to about the same high extent as observed with bacterial transforming DNA.The usefulness of this system for investigating bacterial transformation and biological effects ofin vitro treatment of DNA is discussed.with the technical assistance ofSandra J. Antoine With 4 Figures in the TextPreliminary report presented at the 7th Annual Bacterial Transformation Meeting, Aspen, Colorado, June 17–19, 1963.Supported by a travel grant from the Deutsche Forschungsgemeinschaft.Supported by Research Carreer Development Award GM-K3-7500 and Research Grant RH 00221 from the U.S. Public Health Service.     

Overexpression of Cystathionine γ-Lyase Suppresses Detrimental Effects of Spinocerebellar Ataxia Type 3

Spinocerebellar ataxia type 3 (SCA3) is a polyglutamine (polyQ) disorder caused by a CAG repeat expansion in the ataxin-3 (ATXN3) gene resulting in toxic protein aggregation. Inflammation and oxidative stress are considered secondary factors contributing to the progression of this neurodegenerative disease. There is no cure that halts or reverses the progressive neurodegeneration of SCA3. Here we show that overexpression of cystathionine γ-lyase, a central enzyme in cysteine metabolism, is protective in a Drosophila model for SCA3. SCA3 flies show eye degeneration, increased oxidative stress, insoluble protein aggregates, reduced levels of protein persulfidation and increased activation of the innate immune response. Overexpression of Drosophila cystathionine γ-lyase restores protein persulfidation, decreases oxidative stress, dampens the immune response and improves SCA3-associated tissue degeneration. Levels of insoluble protein aggregates are not altered; therefore, the data implicate a modifying role of cystathionine γ-lyase in ameliorating the downstream consequence of protein aggregation leading to protection against SCA3-induced tissue degeneration. The cystathionine γ-lyase expression is decreased in affected brain tissue of SCA3 patients, suggesting that enhancers of cystathionine γ-lyase expression or activity are attractive candidates for future therapies.     

Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage-dependent recombination

Genetic defects in DNA repair mechanisms and cell cycle checkpoint (CCC) genes result in increased genomic instability and cancer predisposition. Discovery of mammalian homologs of yeast CCC genes suggests conservation of checkpoint mechanisms between yeast and mammals. However, the role of many CCC genes in higher eukaryotes remains elusive. Here, we report that targeted deletion of an N-terminal part of mRad17, the mouse homolog of the Schizosaccharomyces pombe Rad17 checkpoint clamp-loader component, resulted in embryonic lethality during early/mid-gestation. In contrast to mouse embryos, embryonic stem (ES) cells, isolated from mRad17(5'Delta/5'Delta) embryos, produced truncated mRad17 and were viable. These cells displayed hypersensitivity to various DNA-damaging agents. Surprisingly, mRad17(5'Delta/5'Delta) ES cells were able to arrest cell cycle progression upon induction of DNA damage. However, they displayed impaired homologous recombination as evidenced by a strongly reduced gene targeting efficiency. In addition to a possible role in DNA damage-induced CCC, based on sequence homology, our results indicate that mRad17 has a function in DNA damage-dependent recombination that may be responsible for the sensitivity to DNA-damaging agents.     

FK506, transforming growth factor-beta1 and mesangial matrix synthesis: parallels and differences compared with cyclosporine A

Cyclosporine A (CsA)-induced glomerulosclerosis is a well-described side effect of CsA treatment. Current evidence indicates that FK506 causes similar morphologic changes. Recently, we demonstrated that CsA up-regulates the expression of transforming growth factor-beta1 (TGF-beta1), its receptors type I (TbetaR-I) and type II (TbetaR-II), as well as related matrix protein synthesis in mesangial cells (MCs). Here, we assessed the effect of FK506 on the expression of TGF-beta1, TbetaR-I, TbetaR-II, fibronectin (FN) and plasminogen activator inhibitor type-1 (PAI-1) in MCs. Resting MCs were incubated with/without FK506. Time- and concentration-dependent expression was measured at the mRNA and protein level. Compared to untreated controls, FK506 stimulated TGF-beta1 mRNA (maximum at 8 h, 100 ng/mL: 2.13+/-0.15-fold, P<0.005) and protein expression (maximum at 96 h, 100 ng/mL: 1.96+/-0.29-fold, P<0.005). In contrast, TbetaR-I and TbetaR-II protein expression remained unchanged. Concerning matrix protein synthesis, FK506 slightly increased FN production (96 h, 100 ng/mL: 1.38+/-0.28-fold, P<0.05), but not PAI-1 production. These results indicate that, comparable to CsA, FK506 induced glomerulosclerosis is also due to a direct effect on mesangial matrix production, which is at least in part mediated via up-regulation of TGF-beta1 expression. The fact that, unlike CsA, FK506 does not increase the expression of TbetaR-I, TbetaR-II, and PAI-1, deserves further investigation.